CN117202900A - 用于预防、改善或减少辐射诱发的疾病的紫檀芪和水飞蓟宾 - Google Patents

用于预防、改善或减少辐射诱发的疾病的紫檀芪和水飞蓟宾 Download PDF

Info

Publication number
CN117202900A
CN117202900A CN202280022392.4A CN202280022392A CN117202900A CN 117202900 A CN117202900 A CN 117202900A CN 202280022392 A CN202280022392 A CN 202280022392A CN 117202900 A CN117202900 A CN 117202900A
Authority
CN
China
Prior art keywords
pterostilbene
salt
silibinin
radiation
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280022392.4A
Other languages
English (en)
Chinese (zh)
Inventor
J·M·埃斯特拉·阿里格尔
M·E·欧布拉多·帕拉
M·R·萨尔瓦多·帕尔默
A·蒙托罗·帕斯特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Valencia Community Lafite Institute Of Technology And University Hospital Research Foundation
Universitat de Valencia
Original Assignee
Valencia Community Lafite Institute Of Technology And University Hospital Research Foundation
Universitat de Valencia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Valencia Community Lafite Institute Of Technology And University Hospital Research Foundation, Universitat de Valencia filed Critical Valencia Community Lafite Institute Of Technology And University Hospital Research Foundation
Publication of CN117202900A publication Critical patent/CN117202900A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/347—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/602—Glycosides, e.g. rutin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/30—Other Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
CN202280022392.4A 2021-01-18 2022-01-18 用于预防、改善或减少辐射诱发的疾病的紫檀芪和水飞蓟宾 Pending CN117202900A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21382036.8A EP4029496A1 (en) 2021-01-18 2021-01-18 Pterostilbene and silibinin for preventing, ameliorating or reducing radiation-induced diseases
EP21382036.8 2021-01-18
PCT/EP2022/051038 WO2022152943A1 (en) 2021-01-18 2022-01-18 Pterostilbene and silibinin for preventing, ameliorating or reducing radiation-induced diseases

Publications (1)

Publication Number Publication Date
CN117202900A true CN117202900A (zh) 2023-12-08

Family

ID=74205784

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280022392.4A Pending CN117202900A (zh) 2021-01-18 2022-01-18 用于预防、改善或减少辐射诱发的疾病的紫檀芪和水飞蓟宾

Country Status (11)

Country Link
US (1) US20250275940A1 (enExample)
EP (2) EP4029496A1 (enExample)
JP (1) JP2024504645A (enExample)
KR (1) KR20230135110A (enExample)
CN (1) CN117202900A (enExample)
AU (1) AU2022207675A1 (enExample)
CA (1) CA3207734A1 (enExample)
ES (1) ES3029832T3 (enExample)
MX (1) MX2023008447A (enExample)
PL (1) PL4277610T3 (enExample)
WO (1) WO2022152943A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115969741B (zh) * 2023-02-21 2025-02-11 水羊化妆品制造有限公司 小花茉莉花蜡和/或小花茉莉净油组合物及应用
JP7799975B2 (ja) * 2023-03-29 2026-01-16 株式会社大阪ソーダ 皮膚バリヤ機能改善剤、及び肌状態改善剤
EP4541351A1 (en) * 2023-10-18 2025-04-23 Center for Intelligent Research in Crystal Engineering, S.L. Compounds and combination as stimulators of collagen synthesis

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140221426A1 (en) * 2011-09-27 2014-08-07 Virginia Commonwealth University Selective metabolic approach to increasing oral bioavailability of phenylephrine and other phenolic bioactivities
CN109419634A (zh) * 2017-08-31 2019-03-05 富士胶片株式会社 水包油型乳化组合物以及皮肤外用剂

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3926711B2 (ja) * 2002-08-30 2007-06-06 株式会社ファンケル 表皮の偏平化を予防、防止、改善する皮膚老化防止用組成物
JP2006265186A (ja) * 2005-03-24 2006-10-05 Fancl Corp シリマリン含有光老化防止剤キット
US9050284B2 (en) * 2009-02-09 2015-06-09 Sami Labs Limited Orally bioavailable stilbenoids—compositions and therapeutic applications thereof
US20110136751A1 (en) * 2009-10-06 2011-06-09 Green Molecular Use of Polyphenols in the Treatment of Cancer
FR2961814B1 (fr) * 2010-06-29 2014-09-26 Isp Investments Inc Nouveaux peptides activateurs de la sirtuine 6 et composition cosmetique ou pharmaceutiques les comprenant.
WO2014112194A1 (ja) * 2013-01-21 2014-07-24 富士フイルム株式会社 油性組成物、並びにそれを含むエマルション組成物及び皮膚外用組成物
WO2014151891A1 (en) * 2013-03-14 2014-09-25 Walley Darlene Topical products
WO2014168925A1 (en) * 2013-04-08 2014-10-16 Virginia Commonwealth University Compositions to alleviate presystemic metabolism of opioids
MX394291B (es) * 2013-10-30 2025-03-24 Chromadex Inc Composiciones de ribosido de nicotinamida para uso topico en el tratamiento de afecciones de la piel.
KR20170045343A (ko) * 2014-09-04 2017-04-26 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 피부의 장벽 기능의 ｕｖ-유도 상실을 치료하는데 사용하기 위한 국소 프테로스틸벤 조성물
CA3021022C (en) * 2016-04-14 2024-04-23 ChromaDex Inc. Use of nicotinamide riboside, nicotinic acid riboside, nicotinamide mononucleotide, and nicotinoyl compound derivatives in infant formula
BR112019003579A2 (pt) * 2016-08-22 2019-05-21 Elysium Health, Inc. Composições de ribosídeo de nicotinamida e pterostilbeno e métodos para o tratamento dedistúrbios neurodegenerativos
CN108478479A (zh) * 2018-04-02 2018-09-04 青岛科技大学 含有能自行提供弱酸性环境的紫檀芪复合物的眼部抗皱啫喱及其制备方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140221426A1 (en) * 2011-09-27 2014-08-07 Virginia Commonwealth University Selective metabolic approach to increasing oral bioavailability of phenylephrine and other phenolic bioactivities
CN109419634A (zh) * 2017-08-31 2019-03-05 富士胶片株式会社 水包油型乳化组合物以及皮肤外用剂

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
张卫明等主编: "《一带一路经济植物》", vol. 2017, 30 November 2017, 东南大学出版社, pages: 356 *

Also Published As

Publication number Publication date
EP4277610C0 (en) 2025-02-26
ES3029832T3 (en) 2025-06-25
WO2022152943A1 (en) 2022-07-21
PL4277610T3 (pl) 2025-08-18
MX2023008447A (es) 2023-10-09
EP4029496A1 (en) 2022-07-20
JP2024504645A (ja) 2024-02-01
EP4277610A1 (en) 2023-11-22
CA3207734A1 (en) 2022-07-21
AU2022207675A1 (en) 2023-08-17
EP4277610B1 (en) 2025-02-26
KR20230135110A (ko) 2023-09-22
US20250275940A1 (en) 2025-09-04

Similar Documents

Publication Publication Date Title
Ren et al. Resveratrol: molecular mechanisms, health benefits, and potential adverse effects
Chu Quarter-century explorations of bioactive polyphenols: Diverse health benefits
Kim et al. Epigenetic modifications of triterpenoid ursolic acid in activating Nrf2 and blocking cellular transformation of mouse epidermal cells
Lee et al. Ophiopogonin D modulates multiple oncogenic signaling pathways, leading to suppression of proliferation and chemosensitization of human lung cancer cells
Mohan et al. Combinations of plant polyphenols & anti-cancer molecules: A novel treatment strategy for cancer chemotherapy
Vyas et al. Chemical analysis and effect of blueberry and lingonberry fruits and leaves against glutamate-mediated excitotoxicity
EP4277610B1 (en) Pterostilbene and silibinin for preventing, ameliorating or reducing radiation-induced diseases
El-Nashar et al. The impact of polyphenolics in the management of breast cancer: mechanistic aspects and recent patents
US20230025435A1 (en) Compositions and methods for increasing cellular vitality and longevity and decreasing molecular ageing
US20250090490A1 (en) Compositions of Azadirachta Indica and Methods of Treating Cancer
Raimondi et al. Impact of natural dietary agents on multiple myeloma prevention and treatment: Molecular insights and potential for clinical translation
Poortalebi et al. Therapeutic Effect of Resveratrol and its Novel Formulations on Lung Cancer: Focus on Biological Aspects and Underlying Pathways
Safe Natural products as anticancer agents and enhancing their efficacy by a mechanism-based precision approach
US20260034137A1 (en) Compositions and Methods for Cellular Ageing, Stress Resilience, Autophagy, Inflammation and Longevity
Rosado-Ramos et al. Exploring the benefits of cellular models to uncover bioactive polyphenols for neurodegeneration
Wuputra et al. Therapeutic Potential of Resveratrol in Cancer and Neurodegenerative Disorders: A Current Review
Dey Natural products against Huntington's disease (HD): implications of neurotoxic animal models and transgenics in preclinical studies
HK40104200B (en) Pterostilbene and silibinin for preventing, ameliorating or reducing radiation-induced diseases
HK40104200A (en) Pterostilbene and silibinin for preventing, ameliorating or reducing radiation-induced diseases
Imanu et al. Pomegranate extract mechanism in inhibiting the development of oral cancer: A review.
Haq et al. Role of antioxidant in chemotherapy related infertility
Kim et al. Justicia procumbens ameliorates aortic aging via ferroptosis regulation in senescent mice and vascular smooth muscle cells
Farhan et al. Current Understanding of Flavonoids in Cancer Therapy and Prevention. Metabolites 2023, 13, 481
이주원 Metastatic potential of ovarian cancer cells regulated by mitochondrial fission in an inflammatory microenvironment
Imran et al. Preclinical Activities of Epigallocatechin Gallate in Signaling Pathways in Cancer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination